
Please try another search
By Sam Boughedda
Eli Lilly & Co.'s (NYSE:LLY) price target was raised to $370 from $285, with its Buy rating maintained at Citi on Thursday.
An analyst stated in his research note that "it's good to be Lilly in 2022."
"We have increased our peak risk-adjusted tirzepatide forecasts (diabetes/obesity/NASH) to >$25bn (previously $15bn, consensus c.$16bn). Our ongoing feedback from physicians/payers continues to fuel our optimism for broader access, reimbursement and adoption given the previously unforeseen glucose and weight lowering properties (US physician/payer survey, Mar-22)," said the analyst.
The analyst told investors they would use any potential weakness on the back of forthcoming data from Eisai's lecanemab and/or Roche's gantenerumab as an attractive opportunity to add to positions.
In addition, Citi "continue[s] to attribute a c.65% probability that LLY's TRAILBLAZER-ALZ 2 meets its primary endpoint in mid-2022."
Despite a dip earlier in the session, Eli Lilly shares are up 0.85% at the time of writing.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.